These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 19447437

  • 1. The impact of obesity on overall and cancer specific survival in men with prostate cancer.
    Davies BJ, Smaldone MC, Sadetsky N, Dall'era M, Carroll PR.
    J Urol; 2009 Jul; 182(1):112-7; discussion 117. PubMed ID: 19447437
    [Abstract] [Full Text] [Related]

  • 2. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC.
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [Abstract] [Full Text] [Related]

  • 3. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
    Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR.
    J Urol; 2005 Mar; 173(3):732-6. PubMed ID: 15711258
    [Abstract] [Full Text] [Related]

  • 4. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS, Swords K, Schultz H, Carson CC, Wallen EM.
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [Abstract] [Full Text] [Related]

  • 5. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED, Southwest Oncology Group.
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [Abstract] [Full Text] [Related]

  • 6. Body mass index and outcome after ventricular assist device placement.
    Musci M, Loforte A, Potapov EV, Krabatsch T, Weng Y, Pasic M, Hetzer R.
    Ann Thorac Surg; 2008 Oct; 86(4):1236-42. PubMed ID: 18805168
    [Abstract] [Full Text] [Related]

  • 7. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
    Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR.
    Cancer; 2007 Mar 15; 109(6):1192-202. PubMed ID: 17311344
    [Abstract] [Full Text] [Related]

  • 8. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
    Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, Blute ML.
    Cancer; 2006 Aug 01; 107(3):521-9. PubMed ID: 16773619
    [Abstract] [Full Text] [Related]

  • 9. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database.
    Fairey AS, Jacobsen NE, Chetner MP, Mador DR, Metcalfe JB, Moore RB, Rourke KF, Todd GT, Venner PM, Voaklander DC, Estey EP.
    J Urol; 2009 Jul 01; 182(1):85-92; discussion 93. PubMed ID: 19447413
    [Abstract] [Full Text] [Related]

  • 10. Is there any survival advantage of obesity in Southern European haemodialysis patients?
    Chazot C, Gassia JP, Di Benedetto A, Cesare S, Ponce P, Marcelli D.
    Nephrol Dial Transplant; 2009 Sep 01; 24(9):2871-6. PubMed ID: 19369686
    [Abstract] [Full Text] [Related]

  • 11. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
    Palma D, Pickles T, Tyldesley S, Prostate Cohort Outcomes Initiative.
    BJU Int; 2007 Aug 01; 100(2):315-9. PubMed ID: 17617138
    [Abstract] [Full Text] [Related]

  • 12. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    Kositsawat J, Flanigan RC, Meydani M, Choi YK, Freeman VL.
    J Urol; 2007 Dec 01; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
    [Abstract] [Full Text] [Related]

  • 13. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP, Cullen J, Auge BK, L'Esperance JO, Kang SK.
    Cancer; 2007 Sep 01; 110(5):1003-9. PubMed ID: 17614338
    [Abstract] [Full Text] [Related]

  • 14. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy.
    van Roermund JG, Hinnen KA, Battermann JJ, Witjes JA, Bosch JL, Kiemeney LA, van Vulpen M.
    BJU Int; 2010 Jan 01; 105(1):42-8. PubMed ID: 19519759
    [Abstract] [Full Text] [Related]

  • 15. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Jan 01; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 16. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, Aronson WJ.
    BJU Int; 2008 Sep 01; 102(8):969-74. PubMed ID: 18691175
    [Abstract] [Full Text] [Related]

  • 17. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR.
    J Urol; 2005 Apr 01; 173(4):1126-31. PubMed ID: 15758720
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of body mass index in Korean patients with renal cell carcinoma.
    Jeon HG, Jeong IG, Lee JH, Lee CJ, Kwak C, Kim HH, Lee SE, Lee E.
    J Urol; 2010 Feb 01; 183(2):448-54. PubMed ID: 20006879
    [Abstract] [Full Text] [Related]

  • 19. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug 01; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 20. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?
    Pfitzenmaier J, Pritsch M, Haferkamp A, Jakobi H, Fritsch F, Gilfrich C, Djakovic N, Buse S, Pahernik S, Hohenfellner M.
    BJU Int; 2009 Apr 01; 103(7):877-82. PubMed ID: 19007372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.